Nomura Holdings’s Pacira BioSciences PCRX Stock Holding History

Nomura Holdings’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20,000	Closed	-$377K	–	2241
2024 Q4	$377K	Buy	+20,000	New	+$351K	﹤0.01%	1898

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nomura Holdings's PCRX Position: Q4 2025 in Review

Nomura Holdings sold out of Pacira BioSciences (PCRX) in Q4 2025, closing a stake of 18,502 shares — an estimated $477K sold.

Nomura Holdings first reported a position in PCRX in Q1 2014 and held it in 23 quarters. The position peaked at $3.44M in Q1 2021. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2025.

Nomura Holdings reported no remaining Pacira BioSciences position as of Q4 2025 after selling out during the quarter.
Nomura Holdings sold 18,502 Pacira BioSciences shares in Q4 2025, an estimated $477K.
Nomura Holdings first reported a position in Pacira BioSciences in Q1 2014 and held it in 23 quarters.
Nomura Holdings's Pacira BioSciences position peaked at $3.44M in Q1 2021.
260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2025.

Based on Nomura Holdings's 13F filing for Q4 2025, filed 17 Feb 2026.